Results 191 to 200 of about 13,753,339 (302)

N‐acetylcysteine for non‐paracetamol‐induced acute liver failure in children: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Non‐surgical treatment of acute liver failure (ALF) is primarily supportive and depends on the underlying cause. While N‐acetylcysteine (NAC) is proven effective in paracetamol‐induced ALF, its potential benefits in non‐paracetamol ALF for paediatric patients remain unclear.
Alise D. E. de Groot, Désanka M. Stoppels, Arno R. Bourgonje, Willemien F. J. Hof, Martin C. J. Kneyber, Daan J. Touw, Henkjan J. Verkade, Paola Mian   +7 more
wiley   +1 more source

Hepatitis B control in jeopardy. [PDF]

Eur J Clin Microbiol Infect Dis
Karakasidis E, Mazin R.
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

The silent risk: Occult Hepatitis B virus detected in Cornea donors. [PDF]

Hematol Transfus Cell Ther
Meira GLS, Lopes JIF, Repossi MGA, Soares AM, Filho LA.   +4 more
europepmc   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

British Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno, Berta Torres, Maria Martínez‐Rebollar, Paula Arreba, Octavi Roman, Roger LLobet, Leire Berrocal, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Ivan Chivite, Elisa de Lazzari, Josep Mallolas, Ana González‐Cordón   +13 more
wiley   +1 more source

Risk of Hepatitis B Reactivation Following Corticosteroids for Tuberculous Meningitis. [PDF]

Open Forum Infect Dis
Donovan J, Thu NTA, Nghia HDT, Bang ND, Trinh DHK, Ngoc LHB, Oanh PKN, Kestelyn E, Hung TT, Geskus RB, Thuong NTT, Phu NH, Thwaites GE.   +12 more
europepmc   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study. [PDF]

World J Virol
Amalou K, Rekab R, Benmellouka N, Derbal B, Belloula A, Chetroub H, Sabrina F, Belghanem F, Saidani K.   +8 more
europepmc   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen-Positive Patients. [PDF]

J Viral Hepat
Kita Y, Murata A, Nago H, Yamaguchi M, Kato Y, Om R, Terai Y, Ikeda Y, Sato S, Sato S, Shimada Y, Genda T.   +11 more
europepmc   +1 more source